Which has better earnings and valuation, RVTY or BRKR?

Revvity has higher earnings, but lower revenue than Bruker. Bruker is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.86B 3.92 $241.20M $2.09 48.07 Bruker $3.44B 2.54 -$8.60M -$0.24 N/A

Is RVTY or BRKR more profitable?

Revvity has a net margin of 8.26% compared to Bruker's net margin of -0.65%. Bruker's return on equity of 11.60% beat Revvity's return on equity. Company Net Margins Return on Equity Return on Assets Revvity 8.26% 8.00% 4.83% Bruker -0.65% 11.60% 4.25%

Does the media favor RVTY or BRKR?

In the previous week, Bruker had 7 more articles in the media than Revvity. MarketBeat recorded 9 mentions for Bruker and 2 mentions for Revvity. Bruker's average media sentiment score of 1.55 beat Revvity's score of 0.94 indicating that Bruker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bruker 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, RVTY or TECH?

Revvity has higher revenue and earnings than Bio-Techne. Revvity is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.86B 3.92 $241.20M $2.09 48.07 Bio-Techne $1.22B 7.44 $73.40M $0.69 83.97

Is RVTY or TECH more profitable?

Bio-Techne has a net margin of 9.05% compared to Revvity's net margin of 8.26%. Bio-Techne's return on equity of 13.57% beat Revvity's return on equity. Company Net Margins Return on Equity Return on Assets Revvity 8.26% 8.00% 4.83% Bio-Techne 9.05% 13.57% 10.66%

Does the media refer more to RVTY or TECH?

In the previous week, Bio-Techne had 3 more articles in the media than Revvity. MarketBeat recorded 5 mentions for Bio-Techne and 2 mentions for Revvity. Revvity's average media sentiment score of 0.94 beat Bio-Techne's score of 0.83 indicating that Revvity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer A or RVTY?

In the previous week, Agilent Technologies had 14 more articles in the media than Revvity. MarketBeat recorded 16 mentions for Agilent Technologies and 2 mentions for Revvity. Revvity's average media sentiment score of 0.94 beat Agilent Technologies' score of 0.92 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 9 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Revvity 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, RVTY or AVTR?

Revvity has higher earnings, but lower revenue than Avantor. Avantor is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.86B 3.92 $241.20M $2.09 48.07 Avantor $6.55B 1.00 -$530.20M -$0.81 N/A

Is RVTY or AVTR more profitable?

Revvity has a net margin of 8.26% compared to Avantor's net margin of -8.42%. Avantor's return on equity of 9.95% beat Revvity's return on equity. Company Net Margins Return on Equity Return on Assets Revvity 8.26% 8.00% 4.83% Avantor -8.42% 9.95% 4.78%

Does the media refer more to RVTY or AVTR?

In the previous week, Avantor had 7 more articles in the media than Revvity. MarketBeat recorded 9 mentions for Avantor and 2 mentions for Revvity. Avantor's average media sentiment score of 1.57 beat Revvity's score of 0.94 indicating that Avantor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avantor 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to RVTY or CRL?

In the previous week, Charles River Laboratories International had 2 more articles in the media than Revvity. MarketBeat recorded 4 mentions for Charles River Laboratories International and 2 mentions for Revvity. Revvity's average media sentiment score of 0.94 beat Charles River Laboratories International's score of 0.90 indicating that Revvity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Charles River Laboratories International 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Revvity (RVTY) Competitors

$100.47 +0.47 (+0.47%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$99.98 -0.49 (-0.49%)

As of 06/18/2026 04:21 PM Eastern

Compare

RVTY vs. BRKR, TECH, A, AVTR, and CRL

Should you buy Revvity stock or one of its competitors? MarketBeat compares Revvity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Revvity include Bruker (BRKR), Bio-Techne (TECH), Agilent Technologies (A), Avantor (AVTR), and Charles River Laboratories International (CRL).

How does Revvity compare to Bruker?

Revvity (NYSE:RVTY) and Bruker (NASDAQ:BRKR) are related companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

86.7% of Revvity shares are owned by institutional investors. Comparatively, 79.5% of Bruker shares are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Comparatively, 27.2% of Bruker shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Revvity has a net margin of 8.26% compared to Bruker's net margin of -0.65%. Bruker's return on equity of 11.60% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.26%	8.00%	4.83%
Bruker	-0.65%	11.60%	4.25%

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.3%. Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Revvity pays out 13.4% of its earnings in the form of a dividend. Bruker pays out -83.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bruker is clearly the better dividend stock, given its higher yield and lower payout ratio.

Revvity currently has a consensus target price of $107.73, indicating a potential upside of 7.23%. Bruker has a consensus target price of $51.31, indicating a potential downside of 10.35%. Given Revvity's higher probable upside, equities research analysts clearly believe Revvity is more favorable than Bruker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Bruker	2 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, Bruker had 7 more articles in the media than Revvity. MarketBeat recorded 9 mentions for Bruker and 2 mentions for Revvity. Bruker's average media sentiment score of 1.55 beat Revvity's score of 0.94 indicating that Bruker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bruker	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Revvity has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Bruker has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

Revvity has higher earnings, but lower revenue than Bruker. Bruker is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	3.92	$241.20M	$2.09	48.07
Bruker	$3.44B	2.54	-$8.60M	-$0.24	N/A

Summary

Bruker beats Revvity on 11 of the 19 factors compared between the two stocks.

How does Revvity compare to Bio-Techne?

Revvity (NYSE:RVTY) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Revvity has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

Bio-Techne has a net margin of 9.05% compared to Revvity's net margin of 8.26%. Bio-Techne's return on equity of 13.57% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.26%	8.00%	4.83%
Bio-Techne	9.05%	13.57%	10.66%

86.7% of Revvity shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 0.9% of Revvity shares are owned by company insiders. Comparatively, 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Bio-Techne had 3 more articles in the media than Revvity. MarketBeat recorded 5 mentions for Bio-Techne and 2 mentions for Revvity. Revvity's average media sentiment score of 0.94 beat Bio-Techne's score of 0.83 indicating that Revvity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has higher revenue and earnings than Bio-Techne. Revvity is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	3.92	$241.20M	$2.09	48.07
Bio-Techne	$1.22B	7.44	$73.40M	$0.69	83.97

Revvity presently has a consensus target price of $107.73, suggesting a potential upside of 7.23%. Bio-Techne has a consensus target price of $65.15, suggesting a potential upside of 12.45%. Given Bio-Techne's stronger consensus rating and higher possible upside, analysts plainly believe Bio-Techne is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Bio-Techne	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.67

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.3%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.6%. Revvity pays out 13.4% of its earnings in the form of a dividend. Bio-Techne pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Bio-Techne beats Revvity on 14 of the 19 factors compared between the two stocks.

How does Revvity compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Revvity (NYSE:RVTY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Agilent Technologies has a net margin of 19.55% compared to Revvity's net margin of 8.26%. Agilent Technologies' return on equity of 24.33% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.55%	24.33%	12.99%
Revvity	8.26%	8.00%	4.83%

86.7% of Revvity shares are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Agilent Technologies currently has a consensus price target of $160.93, indicating a potential upside of 26.23%. Revvity has a consensus price target of $107.73, indicating a potential upside of 7.23%. Given Agilent Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Agilent Technologies is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Revvity	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

In the previous week, Agilent Technologies had 14 more articles in the media than Revvity. MarketBeat recorded 16 mentions for Agilent Technologies and 2 mentions for Revvity. Revvity's average media sentiment score of 0.94 beat Agilent Technologies' score of 0.92 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	9 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Revvity has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Agilent Technologies has higher revenue and earnings than Revvity. Agilent Technologies is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	5.18	$1.30B	$4.98	25.60
Revvity	$2.86B	3.92	$241.20M	$2.09	48.07

Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.8%. Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.3%. Agilent Technologies pays out 20.5% of its earnings in the form of a dividend. Revvity pays out 13.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has increased its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Agilent Technologies beats Revvity on 15 of the 20 factors compared between the two stocks.

How does Revvity compare to Avantor?

Revvity (NYSE:RVTY) and Avantor (NYSE:AVTR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Revvity has a net margin of 8.26% compared to Avantor's net margin of -8.42%. Avantor's return on equity of 9.95% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.26%	8.00%	4.83%
Avantor	-8.42%	9.95%	4.78%

86.7% of Revvity shares are held by institutional investors. Comparatively, 95.1% of Avantor shares are held by institutional investors. 0.9% of Revvity shares are held by company insiders. Comparatively, 0.3% of Avantor shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Revvity presently has a consensus price target of $107.73, indicating a potential upside of 7.23%. Avantor has a consensus price target of $10.57, indicating a potential upside of 10.24%. Given Avantor's higher possible upside, analysts clearly believe Avantor is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Avantor	3 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.94

In the previous week, Avantor had 7 more articles in the media than Revvity. MarketBeat recorded 9 mentions for Avantor and 2 mentions for Revvity. Avantor's average media sentiment score of 1.57 beat Revvity's score of 0.94 indicating that Avantor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avantor	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Revvity has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Avantor has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Revvity has higher earnings, but lower revenue than Avantor. Avantor is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	3.92	$241.20M	$2.09	48.07
Avantor	$6.55B	1.00	-$530.20M	-$0.81	N/A

Summary

Revvity beats Avantor on 10 of the 16 factors compared between the two stocks.

How does Revvity compare to Charles River Laboratories International?

Revvity (NYSE:RVTY) and Charles River Laboratories International (NYSE:CRL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Revvity presently has a consensus price target of $107.73, indicating a potential upside of 7.23%. Charles River Laboratories International has a consensus price target of $211.00, indicating a potential upside of 13.95%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, analysts clearly believe Charles River Laboratories International is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

86.7% of Revvity shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 0.9% of Revvity shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Revvity has a net margin of 8.26% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.26%	8.00%	4.83%
Charles River Laboratories International	-4.59%	15.36%	6.61%

In the previous week, Charles River Laboratories International had 2 more articles in the media than Revvity. MarketBeat recorded 4 mentions for Charles River Laboratories International and 2 mentions for Revvity. Revvity's average media sentiment score of 0.94 beat Charles River Laboratories International's score of 0.90 indicating that Revvity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	3.92	$241.20M	$2.09	48.07
Charles River Laboratories International	$4.02B	2.22	-$144.34M	-$3.76	N/A

Revvity has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Summary

Charles River Laboratories International beats Revvity on 10 of the 16 factors compared between the two stocks.

Get Revvity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVTY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVTY vs. The Competition

Export

Metric	Revvity	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$11.16B	$8.76B	$6.65B	$23.21B
Dividend Yield	0.28%	1.73%	2.68%	4.06%
P/E Ratio	48.07	24.73	24.75	31.61
Price / Sales	3.92	16.61	529.30	22.84
Price / Cash	11.34	13.96	27.92	18.67
Price / Book	1.57	5.64	10.81	4.69
Net Income	$241.20M	$179.69M	$3.57B	$1.08B
7 Day Performance	0.81%	1.96%	0.72%	-0.82%
1 Month Performance	5.31%	2.99%	0.41%	1.07%
1 Year Performance	5.80%	6.36%	29.34%	25.02%

Revvity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVTY Revvity	3.2756 of 5 stars	$100.47 +0.5%	$107.73 +7.2%	+5.8%	$11.16B	$2.86B	48.07	11,000	Gap Down
BRKR Bruker	2.845 of 5 stars	$56.26 -0.2%	$51.31 -8.8%	+50.3%	$8.58B	$3.44B	N/A	11,085	Gap Up
TECH Bio-Techne	3.3747 of 5 stars	$52.65 +1.3%	$65.17 +23.8%	+16.1%	$8.14B	$1.22B	76.31	3,100	Positive News Gap Down
A Agilent Technologies	4.9672 of 5 stars	$132.88 -1.9%	$161.71 +21.7%	+10.3%	$38.25B	$6.95B	26.68	18,100
AVTR Avantor	3.5054 of 5 stars	$9.70 +5.8%	$10.57 +9.0%	-29.4%	$6.25B	$6.55B	N/A	13,500	News Coverage Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RVTY) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revvity (RVTY) Competitors